FGB抗体

+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane: Mouse heart tissue, Primary antibody: P08337(FGB Antibody) at dilution 1/1000, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 5 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colon cancer tissue using P08337(FGB Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P08337(FGB Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

Fibrinogen beta chain (FGB) antibodies are immunological tools designed to target the beta subunit of fibrinogen, a critical plasma glycoprotein involved in blood coagulation and wound healing. Fibrinogen, composed of two sets of three polypeptide chains (Aα, Bβ, and γ), is synthesized primarily in the liver and circulates in the bloodstream. Upon vascular injury, thrombin cleaves fibrinogen to form fibrin monomers, which polymerize into a clot matrix, stabilizing platelet aggregates and preventing excessive bleeding. The FGB chain plays a key role in fibrinopeptide B release during this process.

FGB antibodies are widely used in research and diagnostics to study fibrinogen structure, function, and expression. They aid in detecting fibrinogen levels in conditions like dysfibrinogenemia, liver disease, or disseminated intravascular coagulation (DIC). Additionally, these antibodies help investigate fibrinogen's role in inflammation, thrombosis, and tumor progression, as elevated fibrinogen is linked to cardiovascular diseases and cancer metastasis.

Commercial FGB antibodies are developed using recombinant FGB proteins or synthetic peptides, validated for specificity in assays like ELISA, Western blot, and immunohistochemistry. Challenges include cross-reactivity with homologous proteins or degraded fibrinogen fragments. Ongoing research focuses on refining antibody specificity and exploring therapeutic applications, such as targeting fibrinogen in thrombotic disorders. Understanding FGB biology through these antibodies remains vital for advancing hematology and vascular medicine.